AlzheimerBEAT ADNCT07834528
Brain Heath Service for Prevention of AD
A study testing medical referral and/or educational programs in people with Alzheimer and Cognitive Unimpaired, run by Chinese University of Hong Kong at 1 site in China.
Trial summary
The aim of the program to serve as a prototype for future preventive program for AD in the region. The program will recruit elderly participants. Cognitive assessment and lifestyle questionnaire will be performed with each participant to investigator their risk factor associate with AD. Read more about this study
- Who is it for?
- Ages 55 to 80 yearsHealthy volunteers can take part
- Conditions the study is for
- Alzheimer, Cognitive Unimpaired, Mild Cognitive Impairment
- What is being tested?
- medical referral and/or educational programs
- Type of treatment
- Lifestyle or therapy programme
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 4,000 participants
- Where
- 1 siteChina
- Study dates
- 21 Sep 2026to 31 Mar 2033
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 55 to 80 years
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- 1. Hong Kong citizens, between 55 - 80 years old.
Who cannot join
- 1. No known diagnosis of dementia or other diseases that may affect cognition, e.g., stroke, Parkinson's disease, brain infection, major head injury, major depression, obstructive sleep apnea, alcoholism (e.g., daily > 2 standard drinks for male and > 1 standard drinks for woman).
- 2. Subject who cannot understand Cantonese
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
About this study
The aim of the program to serve as a prototype for future preventive program for AD in the region. The program will recruit elderly participants. Cognitive assessment and lifestyle questionnaire will be performed with each participant to investigator their risk factor associate with AD.
The program will offer medical referral and/or educational program(s) (e.g. tailor-made multidomain preventive measures plan, education talks) for participants who might have possible early AD or with high risk of AD
Read the detailed description
Epidemiological studies over the past few decades demonstrate that AD is associated with multiple modifiable risk factors, including cardiovascular risk factors, level of physical and cognitively stimulating or social activities, and dietary pattern. Recent large scale randomized controlled clinical trials show that single- or multi-domain lifestyle intervention and control in cardiovascular risk factors can slow down cognitive decline among subjects with early AD who have suboptimal control in AD modifiable risk factors.
This study aims to identify subjects with possible early AD, to investigate the control in AD modifiable risk factors among subjects with early AD, and to implement tailor-made preventive measures among early AD subjects with suboptimal control in risk factors.
Through the BEAT AD program, knowledge on preventive measures of AD can be promoted around Hong Kong.
- Conditions
- Alzheimer, Cognitive Unimpaired, Mild Cognitive Impairment
- Being tested
- medical referral and/or educational programs
- Keywords
- lifestyle modification in prevention of AD
- Medical subject headings
- Cognitive Dysfunction
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
medical referral and/or educational programsBehavioural
tailor-made multidomain preventive measures plan about diet, exercises, cognitive stimulation
| Study group | Role | What they receive |
|---|---|---|
| Healthy Control | No intervention | Cognitive unimpaired |
| MCI | Active comparator | Mild Cognitive impaired Receives: Behavioral: medical referral and/or educational programs |
What is being measured
The primary outcome is the main question the study is designed to answer.
Identification of possible early AD
Using MoCA and retinal Image AD Index to screening participants who have high risk of Alzheimer's Disease
Measured: At baseline
Secondary outcomes (2)
Investigation of the control in AD modifiable risk factors
Using the brain health scores to identify AD modifiable risk factors: (a) cardiovascular risk factors, (b) level of physical activity, (c) level of cognitively stimulating/social activities (CSA)
Measured: At baseline
Implementation of AD preventive measures
Base on the result of brain health score, tailor-made preventive measures among early AD subjects with suboptimal control in risk factors. Compare the results of brain health score after completion of health educational programs. Programs end time varies as they are tailor-made; yet evaluations will be done at 12 month and 24 months after baseline evaluation.
Measured: End of educational program(s) approximately at 12 months and 24 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted22 Sep 2026
- Study start21 Sep 2026
- Primary completion31 Mar 2032 (estimated)
- Study completion31 Mar 2033 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (3)Papers the sponsor has linked to this study.
- Other trials for AlzheimerStudies of the same condition, open and under way.
- More trials run by Chinese University of Hong KongThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Screening
- Allocation
- Non-randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 4,000 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Chinese University of Hong Kong
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Vincent Mok, Chinese University of Hong Kong
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07834528
- Sponsor's protocol ID
- 2023.348
- Acronym
- BEAT AD
- Status last verified
- Sep 2026
- First submitted
- 16 Sep 2026
- Last updated
- 22 Oct 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided
Publications
Kivipelto M, Mangialasche F, Ngandu T. Lifestyle interventions to prevent cognitive impairment, dementia and Alzheimer disease. Nat Rev Neurol. 2018 Nov;14(11):653-666. doi: 10.1038/s41582-018-0070-3.
PubMed 30291317Cheung CY, Ran AR, Wang S, Chan VTT, Sham K, Hilal S, Venketasubramanian N, Cheng CY, Sabanayagam C, Tham YC, Schmetterer L, McKay GJ, Williams MA, Wong A, Au LWC, Lu Z, Yam JC, Tham CC, Chen JJ, Dumitrascu OM, Heng PA, Kwok TCY, Mok VCT, Milea D, Chen CL, Wong TY. A deep learning model for detection of Alzheimer's disease based on retinal photographs: a retrospective, multicentre case-control study. Lancet Digit Health. 2022 Nov;4(11):e806-e815. doi: 10.1016/S2589-7500(22)00169-8. Epub 2022 Sep 30.
PubMed 36192349Ngandu T, Lehtisalo J, Solomon A, Levalahti E, Ahtiluoto S, Antikainen R, Backman L, Hanninen T, Jula A, Laatikainen T, Lindstrom J, Mangialasche F, Paajanen T, Pajala S, Peltonen M, Rauramaa R, Stigsdotter-Neely A, Strandberg T, Tuomilehto J, Soininen H, Kivipelto M. A 2 year multidomain intervention of diet, exercise, cognitive training, and vascular risk monitoring versus control to prevent cognitive decline in at-risk elderly people (FINGER): a randomised controlled trial. Lancet. 2015 Jun 6;385(9984):2255-63. doi: 10.1016/S0140-6736(15)60461-5. Epub 2015 Mar 12.
PubMed 25771249
Study at a glance
From the registry record, last updated by the sponsor on 22 Oct 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Brain Heath Service for Prevention of AD
- ClinicalTrials.gov ID
- NCT07834528
- Acronym / sponsor ID
- BEAT AD / 2023.348
- Conditions
- Alzheimer, Cognitive Unimpaired, Mild Cognitive Impairment
- Keywords
- lifestyle modification in prevention of AD
- Study type
- Interventional
- Recruitment status
- Enrolling by invitation
- Enrolment
- 4,000 participants (estimated)
- Lead sponsor
- Chinese University of Hong KongUniversity, hospital or other
- Study start
- 21 Sep 2026 (actual)
- Primary completion
- 31 Mar 2032 (estimated)
- Study completion
- 31 Mar 2033 (estimated)
- First posted
- 22 Sep 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The aim of the program to serve as a prototype for future preventive program for AD in the region. The program will recruit elderly participants. Cognitive assessment and lifestyle questionnaire will be performed with each participant to investigator their risk factor associate with AD.
The program will offer medical referral and/or educational program(s) (e.g. tailor-made multidomain preventive measures plan, education talks) for participants who might have possible early AD or with high risk of AD
Detailed description
Epidemiological studies over the past few decades demonstrate that AD is associated with multiple modifiable risk factors, including cardiovascular risk factors, level of physical and cognitively stimulating or social activities, and dietary pattern. Recent large scale randomized controlled clinical trials show that single- or multi-domain lifestyle intervention and control in cardiovascular risk factors can slow down cognitive decline among subjects with early AD who have suboptimal control in AD modifiable risk factors.
This study aims to identify subjects with possible early AD, to investigate the control in AD modifiable risk factors among subjects with early AD, and to implement tailor-made preventive measures among early AD subjects with suboptimal control in risk factors.
Through the BEAT AD program, knowledge on preventive measures of AD can be promoted around Hong Kong.
Study design
- Primary purpose
- Screening
- Allocation
- Non-randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Healthy Control | No intervention | –Cognitive unimpaired |
| MCI | Active comparator | Behavioral: medical referral and/or educational programsMild Cognitive impaired |
Who may qualify
- Ages
- 55 to 80 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (1 listed)
- 1. Hong Kong citizens, between 55 - 80 years old.
Key exclusion criteria (2 listed)
- 1. No known diagnosis of dementia or other diseases that may affect cognition, e.g., stroke, Parkinson's disease, brain infection, major head injury, major depression, obstructive sleep apnea, alcoholism (e.g., daily > 2 standard drinks for male and > 1 standard drinks for woman).
- 2. Subject who cannot understand Cantonese
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| medical referral and/or educational programstailor-made multidomain preventive measures plan about diet, exercises, cognitive stimulation | Behavioural | MCI |
Primary outcome
Identification of possible early AD
Time frame: At baseline
Using MoCA and retinal Image AD Index to screening participants who have high risk of Alzheimer's Disease
2 secondary outcomes
Investigation of the control in AD modifiable risk factors
Time frame: At baseline
Implementation of AD preventive measures
Time frame: End of educational program(s) approximately at 12 months and 24 months
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 22 Oct 2026.
- Background: PubMed 30291317Kivipelto M, Mangialasche F, Ngandu T. Lifestyle interventions to prevent cognitive impairment, dementia and Alzheimer disease. Nat Rev Neurol. 2018 Nov;14(11):653-666. doi: 10.1038/s41582-018-0070-3.
- Background: PubMed 36192349Cheung CY, Ran AR, Wang S, Chan VTT, Sham K, Hilal S, Venketasubramanian N, Cheng CY, Sabanayagam C, Tham YC, Schmetterer L, McKay GJ, Williams MA, Wong A, Au LWC, Lu Z, Yam JC, Tham CC, Chen JJ, Dumitrascu OM, Heng PA, Kwok TCY, Mok VCT, Milea D, Chen CL, Wong TY. A deep learning model for detection of Alzheimer's disease based on retinal photographs: a retrospective, multicentre case-control study. Lancet Digit Health. 2022 Nov;4(11):e806-e815. doi: 10.1016/S2589-7500(22)00169-8. Epub 2022 Sep 30.
- Background: PubMed 25771249Ngandu T, Lehtisalo J, Solomon A, Levalahti E, Ahtiluoto S, Antikainen R, Backman L, Hanninen T, Jula A, Laatikainen T, Lindstrom J, Mangialasche F, Paajanen T, Pajala S, Peltonen M, Rauramaa R, Stigsdotter-Neely A, Strandberg T, Tuomilehto J, Soininen H, Kivipelto M. A 2 year multidomain intervention of diet, exercise, cognitive training, and vascular risk monitoring versus control to prevent cognitive decline in at-risk elderly people (FINGER): a randomised controlled trial. Lancet. 2015 Jun 6;385(9984):2255-63. doi: 10.1016/S0140-6736(15)60461-5. Epub 2015 Mar 12.
- Individual participant dataSharing planned: Undecided
Related trials for Alzheimer
RecruitingPhase 2
Neuroplasticity Enhancement From Cognitive Training Reinforced by Psilocybin
Alzheimer's Disease
Not yet recruiting
Acupressure as Long-term Intervention to Slow the Progression of Early/Mild Alzheimer's Disease
Alzheimer's Disease
RecruitingObservational study
Effectiveness and Safety of Disease-Modifying Therapy for Alzheimer's Disease: A Multicenter Retrospective Study
Alzheimer's Disease (AD)
RecruitingPhase 3
A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-1)
Alzheimer Disease
RecruitingPhase 3
A Study of Trontinemab in Cognitively Unimpaired Individuals at Risk for Progression to Symptomatic Alzheimer's Disease
Alzheimer's Disease
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing medical referral and/or educational programs in people with Alzheimer and Cognitive Unimpaired, run by Chinese University of Hong Kong at 1 site in China.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: enrolling by invitation, as of the sponsor's last update on 22 Oct 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Identification of possible early AD (time frame: At baseline). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT07834528, which also lists 3 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 22 Oct 2026.